Trial · NCT05085574
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
NCT05085574, Phase 2, Withdrawn, Leidos Life Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1). Trials, record NCT05085574. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05085574
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
- NCT number
- NCT05085574
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Leidos Life Sciences
- Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV-2 Infection, SARS-CoV-2 Acute Respiratory Disease, COVID-19
- Interventions
- Famotidine, Celecoxib, Placebo
- First posted
- 2021-10-20
- Last updated
- 2023-10-10
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time-to-event to achieve WHO level ≤3 | 30 days | Evaluation of the time-to-event to achieve a WHO level score ≤3 |
| Primary | Death rate | 30 days | Evaluation of the time-to-event where all-cause mortality occurs |
| Secondary | Hospital discharge to chronic palliative care | 30 days | Measured incidence of hospital discharge to chronic palliative care |
| Secondary | Hospital discharge with no additional medical care | 30 days | Measured incidence of hospital discharge with no additional medical care required |
| Secondary | Related adverse events (AEs) and serious adverse events (SAEs) | 90 days | Measured incidence of related AEs and SAEs |
| Secondary | Study discontinuation due to related AEs or SAEs | 90 days | Measured incidence of study discontinuation due to related AEs or SAEs |
| Other | Pharmacokinetic (PK) endpoint-Assess area under the curve | 14 days | Measure area under the curve (AUC) for famotidine and celecoxib combination in 10 patients per group |
| Other | Pharmacokinetic (PK) endpoint-Assess time to maximum plasma concentration | 14 days | Measure time to maximum plasma concentration (tmax) for famotidine and celecoxib combination in 10 patients per group |
| Other | Pharmacokinetic (PK) endpoint-Assess maximum serum concentration | 14 days | Measure maximum serum concentration (Cmax) for famotidine and celecoxib combination in 10 patients per group |
| Other | Exploratory endpoint-Incidence of symptom reduction | 14 days | Cumulative incidence of clinically significant symptom reduction (severity and duration) using COVID-19 Symptom Score |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05085574
GET https://conductscience.org/api/trials/v1/NCT05085574/registered